Free Online FOOD for MIND & HUNGER - DO GOOD 😊 PURIFY MIND.To live like free birds 🐦 🦢 🦅 grow fruits 🍍 🍊 🥑 🥭 🍇 🍌 🍎 🍉 🍒 🍑 🥝 vegetables 🥦 🥕 🥗 🥬 🥔 🍆 🥜 🎃 🫑 🍅🍜 🧅 🍄 🍝 🥗 🥒 🌽 🍏 🫑 🌳 🍓 🍊 🥥 🌵 🍈 🌰 🇧🇧 🫐 🍅 🍐 🫒Plants 🌱in pots 🪴 along with Meditative Mindful Swimming 🏊‍♂️ to Attain NIBBĀNA the Eternal Bliss.
Kushinara NIBBĀNA Bhumi Pagoda White Home, Puniya Bhumi Bengaluru, Prabuddha Bharat International.
Categories:

Archives:
Meta:
March 2024
M T W T F S S
« Jan    
 123
45678910
11121314151617
18192021222324
25262728293031
04/03/20
LESSON 3324 Sat 4 Apr 2020 Free Online NIBBANA TRAINING from KUSHINARA NIBBANA BHUMI PAGODA -PATH TO ATTAIN PEACE and ETERNAL BLISS AS FINAL GOAL DO GOOD! PURIFY MIND AND ENVIRONMENT! Even a seven year old can Understand. A seventy year old must practice. Say YES to Paper Ballots NO to EVMs/VVPATs to save Democracy, Liberty, Equality and Fraternityfor the welfare, happiness and peace for all Awakened aboriginal societies. is the HONEST VOICE of ALL ABORIGINAL AWAKENED SOCIETIES (VoAAAS) Dr B.R.Ambedkar thundered “Main Bharat Baudhmay karunga.” (I will make India Buddhist) All Aboriginal Awakened Societies Thunder ” Hum Prapanch Prabuddha Bharatmay karunge.” (We will make world Prabuddha Prapanch) https://en.wikipedia.org/wiki/World_population World population In demographics, the world population is the total number of humans currently living, and was estimated to have reached 7.86 Billion; COVID-19 Cases:1,015,877minus 212,992 people have recovered. The secret as to how and with what vaccine or medicine have they been cured have to be published. May all those who are alive be ever happy, well and secure! May all live long! May all be calm, quiet, alert, attentive, and have equanimity mind with a clear understanding that everything is changing ! All Governments must provide online food and shelter for migrant workers by distributing the wealth of the countries equally among al sections of the societies as a choice is between starvation and infection. Mahāsatipaṭṭhāna Sutta — Attendance on awareness - 79) Classical Persian-کلاسیک فارسی
Filed under: General
Posted by: site admin @ 7:35 pm

LESSON 3324 Sat 4 Apr 2020

World population
In demographics, the world population is the total number of humans
currently living, and was estimated to have reached 7.86 Billion;
COVID-19 Cases:1,015,877minus 212,992  people have
recovered. The secret as to how and with what vaccine or medicine have they been cured have to be published.

Free Online NIBBANA TRAINING
from

KUSHINARA NIBBANA BHUMI PAGODA -PATH TO ATTAIN PEACE and ETERNAL BLISS AS FINAL GOAL

DO GOOD! PURIFY MIND AND ENVIRONMENT!
Even a seven year old can Understand. A seventy year old must practice.

Say YES to Paper Ballots
NO to EVMs/VVPATs to save Democracy, Liberty, Equality and Fraternityfor
the welfare, happiness and peace for all Awakened aboriginal societies.

is the

HONEST

VOICE of ALL ABORIGINAL AWAKENED SOCIETIES (VoAAAS)

Dr B.R.Ambedkar thundered “Main Bharat Baudhmay karunga.” (I will make India Buddhist)

All Aboriginal Awakened Societies Thunder ” Hum Prapanch Prabuddha Bharatmay karunge.” (We will make world Prabuddha Prapanch)
https://en.wikipedia.org/wiki/World_population

May all those who are alive be ever happy, well and secure!
May all live long!
May all be calm, quiet, alert, attentive, and have equanimity mind with a clear understanding that everything is changing !

All Governments must provide online food and shelter for migrant workers by distributing the wealth of the countries equally among al sections of the societies as a choice is between starvation and infection.



Mahāsatipaṭṭhāna Sutta — Attendance on awareness -
79) Classical Persian-کلاسیک فارسی

https://en.wikipedia.org/wiki/World_population
World population
In demographics, the world population is the total number of humans
currently living, and was estimated to have reached 7.86 Billion; COVID-19 Cases:1,015,877minus 212,992  people have
recovered.

https://www.forbes.com/sites/victoriaforster/2020/03/03/there-is-a-drug-already-used-in-japan-which-may-treat-covid-19-says-new-study/#3295b7154127
Editors’ Pick|185,583 views|Mar 3, 2020,07:30am EST
There Is A Drug Already Used In Japan Which May Treat COVID-19, Says New Study

A group of scientists in Germany have identified a drug called camostat mesylate, that they believe may work to combat COVID-19, the disease caused by the SARS-CoV-2 coronavirus.

The new study published last week in Cell,
shows that SARS-CoV-2 binds to human cells in a similar way to the
original SARS coronavirus (SARS-CoV) that caused a worldwide outbreak in
2003, with this binding depending on viral proteins called ‘spike’
proteins.

“Spike is so named because that’s what it looks like: a spike on the
surface of the virus particle,” said Angela L. Rasmussen, PhD, a
virologist in the faculty of the Center for Infection and Immunity at
the Columbia Mailman School of Public Health. “In order for a virus to
infect a cell, it has to attach itself to a protein on the surface of
that cell which we call the receptor. For SARS-CoV-2, this is a protein
called ACE2. Spike binds ACE2 and allows SARS-CoV-2 to enter and infect
cells,” she added.

As well as this initial process, the spike protein has to be primed
by an enzyme called a protease in order for the virus to complete entry
into the cell. The study showed that similar to SARS-CoV, SARS-CoV-2
uses a protease called TMPRSS2 to complete this process.

The scientists then looked at whether there were any compounds
available that could stop the entry of coronavirus into the cell by
stopping the TMPRSS2 protease from working. From previous work on
SARS-CoV, they found one potential candidate called camostat mesylate
and showed that the drug stopped SARS-CoV-2 from infecting lung cells in
a dish.

“We found that SARS-CoV-2, like SARS-CoV, uses the host proteins ACE2
and TMPRSS2 to enter cells. Both viruses should therefore infect
similar cells in patients and may cause disease via similar mechanisms,”
said Markus Hoffmann, PhD, researcher in the Infection Biology Unit of
the German Primate Center, Leibniz Institute for Primate Research,
Göttingen, Germany and first author of the paper.

Developing new drugs for infectious diseases or even diseases such as
cancer or neurological conditions can take years, even decades. But
camostat mesylate has already been tested in people, albeit not for the
treatment of COVID-19.

“We knew from our previous work that camostat mesylate was active
against other coronaviruses, including SARS-CoV. Therefore, we tested
whether it is also active against SARS-CoV-2,” said Stefan Pöhlmann,
PhD, Professor in the same institute in Göttingen. “Our study shows that
camostat mesylate blocks infection of cells with SARS-CoV-2-like
particles and with authentic, patient-derived SARS-CoV-2. Moreover,
camostat mesylate inhibited infection of important target cells – human
lung epithelial cells,” he added.

The compound is approved in Japan
for the treatment of a number of non-infectious conditions in people,
such as chronic pancreatitis and postoperative reflux esophagitis and
has also had some tests in mice infected with SARS-CoV. However, it has never been tested in humans with COVID-19.

“It does require trials in humans to determine if it’s effective, and
I suspect it would also require pre-clinical animal work with
SARS-CoV-2 specifically before human trials could start. If it has been
shown to be safe for clinical use in other countries, it may be
fast-tracked for FDA approval or the FDA may authorize emergency
off-label use,” said Rasmussen, indicating that the FDA will have to
examine safety data and pre-clinical data before determining which, if
any course of action to take with investigating the drug further.

One concern is that TMPRSS2 might not be the only protease that
controls spike priming and hence blocking it may be ineffective in
people as other proteases may act as backups, still allowing the virus
entry into cells. There are also questions to be asked about how the
drug would actually alter the ability of the virus to cause disease in
people.

“Pathogenesis can’t be studied in cultured cells, so these questions
will need to be addressed using animal models and human clinical
samples,” said Rasmussen.

Given the similarities between SARS-CoV and the current virus
SARS-CoV-2, the researchers also looked at whether people who recovered
from SARS had any immunity to the new virus strain. They took serum
containing antibodies taken from 3 recovering SARS-CoV patients, frozen
back around the time of the original outbreak in 2003 and showed that
this blocked entry of SARS-CoV-2 into cells.

“Antibodies from patients who had recovered from SARS blocked the
SARS-CoV-2 from infecting cells in culture. This suggests that
antibodies against SARS might be useful as a treatment for SARS-CoV-2,”
said Rasmussen.

SARS in 2003 was a smaller outbreak compared to the current situation with only 8,098 cases formally recorded
and over 7,000 people surviving. It is not known how many of these
people are still alive today, but it is possible that they will have
some immunity to COVID-19. On a wider scale, studying these people may
provide incredibly useful clues about successfully treating COVID-19.
So, what are the next steps for the researchers?

“We are currently analyzing whether camostat mesylate-related
inhibitors show improved antiviral activity. So far we have not been
contacted by others regarding off-label use of camostat mesylate.
However, we are contacting physicians to discuss this option,” said
Pöhlmann.

There are currently no FDA-approved treatments for COVID-19, but last
week, the National Institutes of Health announced that the antiviral
drug remdesivir had begun testing in a human clinical trial in the U.S. Remdesivir, marketed by Gilead Sciences has previously shown promise in preventing MERS coronavirus disease in tests on monkeys and is already being used in human trials in Wuhan.
The first patient in the U.S. is an American who was evacuated from the
Diamond Princess cruise ship, which became a floating incubator for the
virus, resulting in over 700 infections and six deaths reported so far.

Follow me on TwitterCheck out my website

I
am a postdoctoral research scientist focusing on childhood cancers and
new, targeted cancer therapies. As a survivor of childhood leukemia
myself, I am a determined

https://www.news.com.au/lifestyle/health/health-problems/coronavirus-australia-queensland-researchers-find-cure-want-drug-trial/news-story/93e7656da0cff4fc4d2c5e51706accb5


Coronavirus Australia: Queensland researchers find ‘cure’, want drug trial

Some
patients who tested positive for coronavirus in Australia have already
been treated with one of the drugs and “all did very, very well,”
researchers say.

Sarah McPhee
news.com.auMarch 17, 20206:26am
Current Time 0:09
/
Duration 0:43
NOW PLAYING
Resume
Researchers trial drugs that ‘effectively kill’ coronavirus (7 News)
0:43
UP NEXT



















Professor
David Paterson, Consultant Infectious Diseases Physician at the RBWH,
is overseeing research into drugs which he says “kill” the coronavirus
and “coul…

A
team of Australian researchers say they’ve found a cure for the novel
coronavirus and hope to have patients enrolled in a nationwide trial by
the end of the month.

University of
Queensland Centre for Clinical Research director Professor David
Paterson told news.com.au today they have seen two drugs used to treat
other conditions wipe out the virus in test tubes.

He said one of
the medications, given to some of the first people to test positive for
COVID-19 in Australia, had already resulted in “disappearance of the
virus” and complete recovery from the infection.

Prof Paterson,
who is also an infectious disease physician at the Royal Brisbane and
Women’s Hospital, said it wasn’t a stretch to label the drugs “a
treatment or a cure”.

“It’s a potentially effective treatment,” he said.

“Patients would end up with no viable coronavirus in their system at all after the end of therapy.”

The drugs are both already registered and available in Australia.

“What
we want to do at the moment is a large clinical trial across Australia,
looking at 50 hospitals, and what we’re going to compare is one drug,
versus another drug, versus the combination of the two drugs,” Prof
Paterson said.

Given their history, researchers have a “long
experience of them being very well tolerated” and there are no
unexpected side effects.

“We’re not on a flat foot, we can sort of move ahead very rapidly with enrolling Australians in this trial,” Prof Paterson said.

“It’s the question we all have – we know it’s coming now, what is the best way to treat it?”

RELATED: Follow the latest coronavirus updates

Professor David Paterson, director of the University of Queensland Centre for Clinical Research and infectious disease physician at the RBWH. Picture: Supplied

Professor
David Paterson, director of the University of Queensland Centre for
Clinical Research and infectious disease physician at the RBWH. Picture:
SuppliedSource:Supplied

Prof Paterson said positive experiences in the fight against coronavirus
have already been recorded overseas, citing China and Singapore. His
research team are confident they can start getting the drugs to patients
in a very safe way on home soil.

“We want to give Australians the
absolute best treatment rather than just someone’s guesses or someone’s
anecdotal experiences from a few people,” Prof Paterson told
news.com.au.

He said they hope to be enrolling patients by the end of March.

“And
that way, if we can test it in this first wave of patients, we do fully
expect that there are going to be ongoing infections for months and
months ahead, and therefore we’ll have the best possible information to
treat subsequent patients,” Prof Paterson said.

“That’s really our aim, to get real world experience in Australia.”

He
said the trouble with the data coming from China was that it wasn’t
really gathered “in a very controlled way”, given they were the
epicentre of the coronavirus outbreak at the time.

“Things were just chaotic,” Prof Paterson said.

“There were these emergency hospitals being built and the system really being very, very stretched.”

RELATED: Countries where coronavirus has been confirmed

A medical worker takes a swab from a previously recovered coronavirus patient in Wuhan on March 14, 2020. Picture: STR/AFP

A medical worker takes a swab from a previously recovered coronavirus patient in Wuhan on March 14, 2020. Picture: STR/AFPSource:AFP

One
of the two medications is a HIV drug, which has been superseded by
“newer generation” HIV drugs, and the other is an anti-malaria drug
called chloroquine which is rarely used and “kept on the shelf now” due
to resistance to malaria.

He said the researchers want to study
them in a “very meaningful way” against the coronavirus to “try and
alleviate that anxiety of Australians”.

“There have already been
patients treated with these in Australia and there’s been successful
outcomes but it hasn’t been done in a controlled or a comparative way,”
Prof Paterson said.
The drugs would be given orally, as tablets.

Prof
Paterson said patients would be asked to participate “as soon as
they’re admitted” to hospital with the aim of beginning treatment “very
early on in their illness”.

He said the research was sparked by
Chinese patients, who were first given the drug in Australia, showing
their doctors information on the internet about the treatment used
overseas.

“Our doctors were very, very surprised that a HIV drug
could actually work against the novel coronavirus and there was a bit of
scepticism,” he said.

“That first wave of Chinese patients we had
(in Australia), they all did very, very well when they were treated
with the HIV drug.

“That’s reassuring … that we’re onto something really good here.”

RELATED: What are the coronavirus symptoms?

RELATED: How to self-isolate due to coronavirus

Patients are being tested for coronavirus across the world including in Seattle, Washington. Picture: John Moore/Getty Images/AFP

Patients
are being tested for coronavirus across the world including in Seattle,
Washington. Picture: John Moore/Getty Images/AFPSource:AFP

The
RBWH Foundation has established a Coronavirus Action Fund. By Monday
afternoon it had raised $30,000 of the desired $750,000 for the clinical
drug trials and other related medical research.

“The trials will start as soon as funding is secured,” the fund states.

When
asked why they had to put a call out money, Prof Paterson said they
“want to give as many people in Australia access to this” and can’t take
doctors away from their normal work.

“The reality is that doctors
are going to need to be concentrating on their patients and we need to
get a very strong research team across Australia that can make sure that
all the Is are dotted and the Ts are crossed and make sure that it is a
really high-quality study so that we can be really confident in the
results,” he said.

“We did this with bushfires, this is an example
where we’re reaching out to the public to put the financial support
behind the study so it can get underway.

“Fifty hospitals have expressed interest in participating and we expect there may even be more to come.”

NED-1370-COVID19: Identifying the symptoms - 0


Leave a Reply